|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8003679||BOEHRINGER INGELHEIM||Use of inhibitors of the renin-angiotensin system|| |
(11 months ago)
Micardis is owned by Boehringer Ingelheim.
Micardis contains Telmisartan.
Micardis has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Micardis are:
Micardis was authorised for market use on 10 November, 1998.
Micardis is available in tablet;oral dosage forms.
Micardis can be used as treatment or prevention of stroke.
The generics of Micardis are possible to be released after 06 October, 2022.
Market Authorisation Date: 10 November, 1998
Treatment: Treatment or prevention of stroke
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic